<SEC-DOCUMENT>0001493152-20-003951.txt : 20200521
<SEC-HEADER>0001493152-20-003951.hdr.sgml : 20200521
<ACCEPTANCE-DATETIME>20200313172852
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-20-003951
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RITTER PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1880 CENTURY PARK EAST, SUITE 1000
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
		BUSINESS PHONE:		310-203-1000

	MAIL ADDRESS:	
		STREET 1:		1880 CENTURY PARK EAST, SUITE 1000
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90067
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="rsLogo" STYLE="height: 34px; width: 180px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">599
Lexington Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022-7650</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1
212 521 5400</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax
+1 212 521 5450</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reedsmith.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
13, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>VIA
EDGAR</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
and Exchange Commission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Division
of Corporation Finance</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100
F Street, N.E.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Mr. Jeffrey P. Riedler</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ritter
    Pharmaceuticals, Inc.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    Statement on Form S-4</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed
    February 4, 2020</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>File
    No. 333-236235</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Ms. Sarmento and Ms. Murphy:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of our client, Ritter Pharmaceuticals, Inc. (&ldquo;Ritter&rdquo; or the &ldquo;Company&rdquo;), we submit this
letter in response to comments from the staff (the &ldquo;Staff&rdquo;) of the Securities and Exchange Commission (the &ldquo;Commission&rdquo;)
contained in its letter dated February 28, 2020 (the &ldquo;Comment Letter&rdquo;), relating to the above-referenced Registration
Statement on Form S-4 (the &ldquo;Registration Statement&rdquo;). We are concurrently filing via EDGAR this letter and Amendment
No. 1 to the Registration Statement (the &ldquo;Amended Registration Statement&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below in bold are comments from the Comment Letter. For your convenience, each of the numbered paragraphs below corresponds
to the numbered comment in the Staff&rsquo;s Comment Letter and includes the caption used in the Comment Letter. Immediately following
each comment is the Company&rsquo;s response to that comment, including, where applicable, a cross-reference to the location of
changes made in the Amended Registration Statement in response to the Staff&rsquo;s comment. All page references in the responses
set forth below refer to page numbers in the Amended Registration Statement. Defined terms used but not otherwise defined herein
have the meanings ascribed to such terms in the Amended Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Registration
Statement on Form S-4</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Questions
and Answers about the Merger</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Q:
What is the Pre-Closing Qualigen Financing?, page 12</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    file the financing commitment letter as an exhibit or tell us why you don&rsquo;t believe it&rsquo;s necessary.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has filed the financing commitment
    letter and will also file (by amendment) an amendment to the financing commitment letter recently entered into as exhibits
    to the Amended Registration Statement. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 27; width: 670"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Risks
Related to Qualigen</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Qualigen
relies on its distribution partner Sekisui, page 54</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    file the distribution agreement with Sekisui as an exhibit or tell us why you don&rsquo;t believe it&rsquo;s necessary.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has filed the distribution agreement
    with Sekisui as an exhibit to the Amended Registration Statement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Background
of the Transaction, page 93</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your disclosure that, beginning on October 7, 2019, Ritter management consulted with certain members of the Ritter Board
    on two occasions and following such consultations, selected a subset of candidates to progress to in-person presentations
    and to receive an initial draft of a letter of intent, respectively. Please disclose which members of the Ritter Board were
    consulted on both occasions and what criteria was used to determine the two subsets of candidates.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your disclosure that members of the Transaction Committee received copies of the full proposals submitted by Party B,
    Party C and Party D and a summary of each of the 13 proposals submitted to AGP, including Qualigen&rsquo;s proposal, on October
    26, 2019. Please disclose who determined to provide full copies of only three proposals and how that determination was made.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your disclosure that the Transaction Committee directed Ritter management to continue to explore a potential transaction
    with each of Qualigen and Parties A, B, C, D, E and F on October 30, 2019, but Qualigen was informed that Ritter would be
    pursing an alternative transaction and would not be pursuing a transaction with Qualigen on November 1, 2019. Please disclose
    what transpired between October 30, 2019 and November 1, 2019 to change the Transaction Committee&rsquo;s decision and what
    factors were considered. Please also revise to disclose the material terms of the bids from Qualigen and Parties A, B, C,
    D, E and F. To the extent that you have not already done so, please disclose how the material terms of the Qualigen bid were
    negotiated, including how the deal value, pricing mechanism, exchange ratio and ownership split were negotiated.</B></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    disclose what parts of the proposals from Parties B, C and D led the Transaction Committee to determine that Parties B, C
    and D were the candidates the most likely to have the ability to consummate a merger with Ritter within a compressed timeframe
    and on terms most likely to maximize shareholder value. Please also discuss whether Ritter considered reaching out to the
    other parties who submitted proposals to see whether they could make their offers more competitive.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your disclosure that AGP conducted a valuation analysis of each proposal. Please expand your disclosure to describe the
    analyses performed, including comparables selected for evaluation, the assumptions underlying such analyses and the resulting
    valuation or valuation range resulting from the analyses.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Ritter
Business, page 151</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your disclosure on page 39 that Ritter may continue to seek partnering, collaborative or similar strategic arrangements
    with third parties to develop and commercialize RP-G28 either as a prescription drug or OTC product or as a dietary supplement
    if the merger is not completed. Please disclose in this section if the combined company has any plans for RP-G28 if the merger
    is completed.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to explain that the combined company does not intend to continue the clinical development
    of RP-G28 and will look to sell, license or transfer the RP-G28 assets.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    remove statements in this section that RP-G28 could become the first drug approved by the FDA for the treatment of LI if approved
    and RP-G28 was expected to have the potential to become the first FDA-approved drug for the reduction of symptoms associated
    with LI. Since you disclose that all further development efforts for RP-G28 have been suspended, it is not appropriate to
    make these statements. Please also remove the statement that clinical testing demonstrated that Lactagen was an effective
    and safe product for reducing symptoms for nearly 80% of the clinical participants who were on Lactagen. Determinations of
    safety and efficacy are solely within the authority of the FDA, and and it appears that Lactagen never received FDA approval.</B></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to remove these statements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Galacto-oligosaccharides
(GOS), page 153</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    revise Figure 1 on page 154 to better differentiate the control, glucose, GOS1 and GOS2 lines.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has included a new Figure 1 in the
    Amended Registration Statement that better differentiates the control, glucose, GOS1 and GOS2 lines.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Qualigen&rsquo;s
Business</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Products
and Solutions, page 169</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your disclosure here that your products have been shown preclinically to have the potential to work together, alone or
    in combination with other therapies, multiplying their effectiveness. Please remove any reference to effectiveness for product
    candidates which have yet to receive FDA approval, and please do not refer to such product candidates as &ldquo;products.&rdquo;
    Similarly, please remove any references to increased potency in preclinical studies for ALAN on page 170. Determinations of
    efficacy are solely within the authority of the FDA.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to remove these statements.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note references to preclinical studies here and on page 170. To the extent that you reference preclinical data suggestive
    of the potential of your product candidates, please revise to discuss the studies and present the data supporting your statements.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Overview,
page 169</U></B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    make it clear in this section and in the Products and Solutions section that the only product that is currently commercially
    available is the FastPack System. Please revise to disclose in this section the current stage of development for each of your
    product candidates: ALAN, RAS-F3 and STARS.</B></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to clarify that the FastPack System is the only product that is currently commercially
    available and to provide the other information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ALAN
(AS1411-GNP), page 170</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    revise your disclosure of the ULRF License Agreement and ACT License Agreement to provide the royalty term, the duration of
    the agreement and the termination provisions. We also note your disclosure that Qualigen has agreed to pay ULRF and ACT payments
    ranging from $100,000 to $5,000,000 upon the achievement of certain milestones. If $5,000,000 is not the aggregate future
    milestone payments to be made, please revise your disclosure to include that number. Please also file both license agreements
    as exhibits or tell us why you don&rsquo;t believe it&rsquo;s necessary.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment. The Company has also filed both
    license agreements as exhibits to the Amended Registration Statement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Regulatory
Strategy, page 171</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your disclosure that Qualigen has demonstrated success in regulatory affairs, having obtained 17 FDA approvals and 19
    CE-Marks for its products to date. Please revise to disclose for which products these approvals and marks have been received
    and that Qualigen has never received FDA or other regulatory approval for a drug candidate.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your disclosure that your strategy for ALAN will not require Phase 3 trials. Please disclose your basis for this statement
    and that there is no guarantee that the FDA will not require you to conduct Phase 3 trials for ALAN.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment and to clarify that there is no
    guarantee that the FDA will not require Qualigen, Inc. (&ldquo;Qualigen&rdquo;) to conduct Phase 3 trials for ALAN.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Intellectual
Property, page 173</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    revise to disclose the specific products, product groups and technologies to which your patents relate, whether they are owned
    or licensed, the type of patent protection you have, the expiration dates, the applicable jurisdictions and whether there
    are any contested proceedings or third-party claims.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Qualigen
Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations, page 193</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tell
    us whether you track any of your R&amp;D costs incurred by program area. If so, tell us your consideration given for disclosing
    a breakdown of this information in your filing to provide additional context to your R&amp;D activities. If not, tell us your
    consideration for disclosing the fact that you do not track these costs by pipeline program area and for providing other quantitative
    or qualitative disclosure that provides transparency as to the types of costs incurred and concentrations of effort expended.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that Qualigen does track R&amp;D costs incurred
    by program area and the Company has revised its disclosures in the Amended Registration Statement to provide the information
    requested by this comment.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>19.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revise
    your MD&amp;A to address the following:</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discuss
    the fluctuations in your cost of goods sold, both in terms of dollars as well as percentage of product sales.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discuss
    the extent to which the amounts were affected by changes in your inventory reserves.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discuss
    the reasons for the significant reserves against your inventory, as well as the reasons for the changes in the reserves between
    periods.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Unaudited
Pro Forma Condensed Combined Financial Statements</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Unaudited
Pro Forma Condensed Combined Balance Sheet, page 208</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>20.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Given
    that you have determined that Qualigen is the accounting acquirer, revise your pro forma presentations to start with the Qualigen
    historical financial statements as the first column, basing the presentation on the periods presented for Qualigen.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the pro forma
    presentations in the Amended Registration Statement to start with the Qualigen historical financial statements as the first
    column, basing the presentation on the periods presented for Qualigen.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>21.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    revise to address the following regarding your footnotes:</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note your footnotes here on page 208 as well as different footnote descriptions on page 215 which appear to be referring to
    the same adjustments. Revise to provide a comprehensive footnote description that more clearly addresses each adjustment.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revise
    to ensure that your adjustments are self-balancing and that you disclose an amount or amounts for each of your adjustments
    as part of your description, providing sufficient detail so as to allow the reader to recalculate.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the footnotes to the
    unaudited pro forma condensed combined financial statements to provide a comprehensive description for each adjustment and
    to disclose the amounts and details of each adjustment. Please refer to Note 3, Pro forma adjustments, to the unaudited pro
    forma condensed combined financial statements included in the Amended Registration Statement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    address the following regarding adjustment K:</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revise
    to clearly explain how the $37,989,079 amount was determined.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revise
    to disclose the transaction reflected in adjustment K in greater detail.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Explain
    to us the basis for your pro forma adjustments for this amount.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tell
    us how you determined that there is no ongoing income statement effect from the financing that would warrant adjustment in
    your pro forma income statements.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the pro forma adjustment
for the Pre-Closing Qualigen Financing pursuant to the Finance Commitment Letter dated January 15, 2020, as amended. Please refer
to adjustment (e) in Note 3, Pro forma adjustments, to the unaudited pro forma condensed combined financial statements included
in the Amended Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Financing Commitment Letter provides that, for the commitment to fund the Pre-Closing Qualigen Financing, the investor will receive
a commitment fee from Qualigen equivalent to 5% of the issued and outstanding Ritter common stock as of immediately after the
Closing on a fully diluted basis. Such commitment fee will be paid in Qualigen Series Alpha preferred stock and will be exchanged
in the merger for Ritter Series Alpha preferred stock. Based on a preliminary evaluation of the Series Alpha preferred stock,
the Series Alpha preferred stock is not a liability within the scope of ASC 480 and is not classified as temporary equity based
on the guidance in ASC 480-10-S99. As such, the share-settled 5% fee is recognized net in equity and therefore do not require
adjustment in the unaudited pro forma condensed combined income statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
warrants to be issued to the investor are classified in equity based on a preliminary determination that the exercise features
and other terms of the warrants are indexed to Qualigen&rsquo;s own stock and classified in stockholders&rsquo; equity and therefore
do not require adjustment in the unaudited pro forma condensed combined income statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>23.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    explain to us the basis for your pro forma additional paid-in capital methodology and the underlying adjustments. For example,
    explain why you include both Ritter and Qualigen&rsquo;s additional paid-in capital as part of the pro forma combined. Explain
    why Ritter&rsquo;s additional paid-in capital is not eliminated.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that
                                         it has revised the unaudited pro forma condensed combined financial statements included
                                         in the Amended Registration Statement. Ritter&rsquo;s additional paid-in capital has
                                         been eliminated in adjustment (b) in Note 3, Pro forma adjustments, to the unaudited
                                         pro forma condensed combined financial statements included in the Amended Registration
                                         Statement.</FONT></P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>24.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    explain to us the basis for your pro forma accumulated deficit amount and the underlying adjustments. For example, explain
    why you include Ritter&rsquo;s accumulated deficit as part of the pro forma combined, and adjustments F and L. Explain why
    Ritter&rsquo;s accumulated deficit is not eliminated.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the unaudited pro forma
    condensed combined financial statements included in the Amended Registration Statement. Ritter&rsquo;s accumulated deficit
    has been eliminated in adjustment (b) in Note 3, Pro forma adjustments, to the unaudited pro forma condensed combined financial
    statements included in the Amended Registration Statement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Unaudited
Pro Forma Condensed Combined Statements of Operations, page 209</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>25.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pro
    forma weighted average common shares outstanding on a combined basis should retroactively reflect the recapitalization and
    related transactions (e.g., conversion of preferred stock and convertible notes from the beginning of the periods presented
    or the date of issuance if later). Accordingly, please provide pro forma shares outstanding to reflect the recapitalization
    and related transactions, and include a tabular reconciliation of the amount in the notes.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the pro forma combined
    weighted average common shares outstanding to reflect the recapitalization and related transactions. Please refer to adjustment
    (j) in Note 3, Pro forma adjustments, to the unaudited pro forma condensed combined financial statements included in the Amended
    Registration Statement for the tabular reconciliation supporting the amount of the pro forma combined weighted average common
    shares outstanding.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Notes
to Unaudited Pro Forma Combined Condensed Financial Statements</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>1.
Description of Transaction, page 212</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>26.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    address the following regarding the 5% commitment fee and the 7.5% advisory fee:</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revise
    to disclose how you will account for these fees, and provide the related amounts.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Explain
    to us the basis for your accounting for these fees, referencing the accounting literature on which you relied.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tell
    us how you determined whether to give pro forma effect to these fees in your pro forma presentations.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The 5% commitment
    fee is related to the Pre-Closing Qualigen Financing, which is addressed in our response to comment #22, above.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">The consulting
    agreement that called for the 7.5% advisory fee was amended subsequent to our filing of the Registration Statement.&nbsp;&nbsp;The
    unaudited pro forma condensed combined financial statements included in the Amended Registration Statement have been revised
    to disclose the amount of the advisory fee and disclose how we account for the advisory fee.&nbsp;&nbsp;&nbsp;Please refer
    to adjustment (h) in Note 3, Pro forma adjustments, to the unaudited pro forma condensed combined financial statements included
    in the Amended Registration Statement.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Under the amended consulting agreement,
Qualigen has agreed to issue to the advisor a number of shares of the Qualigen common stock equivalent to 4.5% of the issued and
outstanding Ritter common stock as of immediately after the closing of the Merger on a fully diluted basis and five-year Qualigen
common stock warrants exercisable for a number of shares of Qualigen common stock that will represent, after assumption of the
warrants by Ritter in the merger and adjustments of the warrants to reflect the Exchange Ratio, warrants to purchase a number
of shares of Ritter common stock that is, as of immediately after the merger, 3% of Ritter&rsquo;s fully-diluted common stock.
The warrants will be exercisable 183 days after the Merger and such warrants shall have an initial exercise price per share equal
to the exercise price in the warrants issued in the Pre-merger financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">The warrants to be issued to the advisor
are a performance award and will vest upon closing of the merger. The estimated fair value of the warrants are recognized in accordance
with ASC 718, Stock Based Compensation, as amended by ASU 2018-07 and are classified in equity based on a preliminary determination
that the exercise features and other terms of the warrants are indexed to Qualigen&rsquo;s own stock and classified in stockholders&rsquo;
equity in accordance with ASC 815-40, Contracts in Entity&rsquo;s Own Equity. The unaudited pro forma condensed combined financial
statements included in the Amended Registration Statement have been revised to recognize the advisory fees as non-employee compensation
cost, based on the estimated fair value of the Qualigen common stock and common stock warrants to be issued the advisor, with
a pro forma adjustment to accumulated deficit. The fair value of Qualigen common stock and common stock warrants is based upon
the valuation of the combined company utilized in the Pre-merger financing of $16.0 million. Please refer to adjustment (h) in
Note 3, Pro forma adjustments, to the unaudited pro forma condensed combined financial statements included in the Amended Registration
Statement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>2.
Basis of Presentation, page 213</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>27.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    address the following:</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
    disclose throughout your document that you determined to apply reverse recapitalization accounting for the merger. However,
    you disclose on page 207 that you will account for the merger as a reverse acquisition, recognizing intangibles. Please revise
    to reconcile this apparent inconsistency.</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>In
    light of the fact that Ritter Pharmaceuticals, Inc. was an operating company for the periods presented and not a shell company,
    explain to us how you determined recapitalization accounting for your transaction is appropriate.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
    part of your response, explain how you considered the business combination accounting guidance in ASC 805 and determined that
    it was not applicable to your situation.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Specifically
    address how you considered that the contingent value rights agreement discussed on page 129 seems to imply that the legacy
    business of Ritter still has some value and continuity.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acknowledges the Staff&rsquo;s
comment and respectfully advises the Staff that it has revised the unaudited pro forma condensed combined financial statements
to describe the merger as a reverse recapitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ritter&rsquo;s recognized assets currently
consist primarily of cash and cash equivalents and prepaid expenses. RP-G28, Ritter&rsquo;s intellectual property (RP-G28), has
no recognized carrying value on Ritter&rsquo;s books and management of the combined Company (Qualigen) has no plans to further
develop RP-G28 when the proposed merger is completed. It is expected that immediately prior to closing the merger, Ritter will
have minimal prepaids and cash, after settling its existing payables from past operations and from the merger transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ritter does not meet the SEC&rsquo;s definition
of a shell company because it had significant pre-combination assets and/or activities. However, Ritter will have nominal assets
upon closing of the merger and ceased having future operating prospects in September 2019, when Ritter&rsquo;s Phase 3 clinical
trial of RP-G28 for lactose intolerance failed to demonstrate statistical significance in its pre-specified primary and secondary
endpoints.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ritter is not a business in accordance
with ASC 805-10-55-5A, as substantially all of the asset fair value of Ritter, upon closing of the proposed merger, will be concentrated
in a single asset group (corporate assets consisting of prepaids and a right-of-use asset). Ritter also does not meet the definition
of a business in ASC 805-10-55-4. The nominal acquired assets do not include an organized workforce or other substantive processes.
Qualigen is not acquiring any productive assets and is not acquiring any signficant contracts, other than the single lease on
Ritter&rsquo;s corporate office space. Ritter ceased further development efforts of its intellectual property in September 2019,
when Ritter&rsquo;s Phase 3 clinical trial of RP-G28 for lactose intolerance failed to demonstrate statistical significance in
its pre-specified primary and secondary endpoints. Any significant payments to CVR holders are expected to be remote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 9.015 of KPMG&rsquo;s Handbook,
Business Combinations, July 2019 provides the following guidance that is relevant to this proposed merger: &ldquo;Even if a public
company does not meet the SEC&rsquo;s definition of a shell company, the public company may have little to no assets (other than
cash or cash equivalents) or activities by the time the reverse acquisition is consummated. If the public company's assets or
activities just prior to the reverse acquisition meet the definition of a business, and the private company is the acquirer for
accounting purposes, the transaction constitutes a business combination. However, if the assets and activities of the public company
are not sufficient to meet the definition of a business, and the private company is the acquirer for accounting purposes, the
accounting acquirer would account for this transaction as the acquisition of a group of assets.&rdquo; In an asset acquisition,
the assets acquired and liabilities assumed are recognized at fair value and no goodwill is recognized. Since Ritter&rsquo;s assets
will have nominal value upon closing of the merger, Qualigen recognizes the asset acquisition as a reverse recapitalization. Qualigen
will credit equity for the fair value of the net monetary assets of Ritter. Costs directly related to this transaction will be
charged to equity only to the extent of cash received, while all costs in excess of cash received will be charged to expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">The proposed CVR agreement does not imply
that the legacy business of Ritter still has some value and continuity upon close of the merger. The RP-G28 intellectual property
is not considered to have any significant value by Qualigen and Qualigen&rsquo;s management has no plans to further develop RP-G28
if the merger is completed. Qualigen will not assign any value to RP-G28 or the CVR in recording the transaction.</P>



<FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>28.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    explain to us why Ritter&rsquo;s estimated transaction costs are part of the purchase price.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">The
                                         Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that
                                         it has revised the unaudited pro forma condensed combined financial statements included
                                         in the Amended Registration Statement. Ritter&rsquo;s estimated transaction costs are
                                         recognized in pro forma combined accumulated deficit. In a reverse recapitalization,
                                         costs directly related to the transaction are charged to equity only to the extent of
                                         cash received, while all costs in excess of cash received are charged to expense. Ritter&rsquo;s
                                         cash balance is estimated to be de minimus at the closing date. Please refer to adjustment
                                         (d) in Note 3, Pro forma adjustments, to the unaudited pro forma condensed combined financial
                                         statements included in the Amended Registration Statement.</P>


</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>29.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    disclose how the contingent value rights (CVRs) will be accounted for as part of the recapitalization transaction, and on
    a go forward basis. Tell us the accounting guidance on which you relied.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">The
                                         Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that
                                         the CVRs are not given any recognition in the unaudited pro forma condensed combined
                                         financial statements included in the Amended Registration Statement. Qualigen will not
                                         assign any value to RP-G28, the intellectual property linked to the CVR, and thus will
                                         not recognize a liability for the CVR.</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>4.
Adjustments to Unaudted Pro Forma Combined Financial Statements, page 215</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>30.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    explain to us why you do not show the pro forma impact from the reverse stock split.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">The Company acknowledges the Staff&rsquo;s comment and
                                                                              respectfully advises the Staff that it has revised the unaudited pro forma condensed combined financial statements included
                                                                              in the Amended Registration Statement to reflect the impact, estimated to be one-for-25, of the proposed Ritter Reverse Stock
                                                                              Split.</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Principal
Stockholders of Qualigen, page 228</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>31.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    revise your disclosure to identify the natural person or persons who have voting and investment control of the shares held
    by Sekisui Diagnostics, LLC and Alpha Capital Anstalt.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>Principal
Stockholders of Combined Company, page 232</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>32.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    revise your disclosure to identify the natural person or persons who have voting and investment control of the shares held
    by GreenBlock Capital LLC. </B></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has revised the disclosures
    in the Amended Registration Statement to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Index
to Qualigen, Inc.</U></B></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U> Consolidated Financial Statements,
page F-34</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>33.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>We
    note that you have not provided audited financial statements for Qualigen, Inc. Please revise to provide audited financial
    statements as required. Refer to Item 17 of Form S-4.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that it has included audited financial statements
    for Qualigen in the Amended Registration Statement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annual
Financial Statements of Qualigen, Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Notes
to Financial Statements</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>General,
page F-39</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U></U></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>34.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    provide the entity-wide disclosures required by ASC 280-10-50-40 through 50-42.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Annual Financial Statements of
    Qualigen included in the Amended Registration Statement have been revised to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>1.
Organization and Summary of Significant Accounting Policies</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Net
Product Sales, page F-41</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>35.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
    part of your disclosure, please describe your distributor allowances and how you determine an estimate of the allowance.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Annual Financial Statements of
    Qualigen included in the Amended Registration Statement have been revised to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Multiple
Element Arrangements, page F-42</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>36.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your
    accounting policy for the allocation of arrangement consideration refers to &ldquo;relative fair value basis&rdquo; here and
    &ldquo;relative selling price&rdquo; under Revenue Recognition, above. Please ensure that your wording is consistent and confirms
    your compliance with ASC 605-25-55-3 and ASC 605-25-15-3A(b).</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Annual Financial Statements of
    Qualigen included in the Amended Registration Statement have been revised to address this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>37.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Your
    determination of selling price using VSOE is not clear as you refer to the current sales prices &ldquo;as if they were sold
    separately.&rdquo; Please clarify your policy so that it is consistent with ASC 605-25-30-6A.</B></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Annual Financial Statements of
    Qualigen included in the Amended Registration Statement have been revised to address this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Research
and Licenses, page F-42</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>38.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    explain to us how you determined that amounts received from your various agreements should be characterized as revenue on
    the statements of operations, and not, for example, a reimbursement of costs presented net.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">The
                                         Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that,
                                         after an evaluation of the facts and circumstances of each agreement, we concluded that
                                         the agreements are within the scope of ASC 808-10. Based on the guidance in ASC 808-10-55,
                                         we determined that the parties from which we received collaborative payments qualified
                                         as customers and the activities that we performed under the agreements represented distinct
                                         services to these parties. The services provided were an output of our ordinary activities
                                         in exchange for consideration. Therefore, the amounts received were characterized as
                                         revenue instead of as a reimbursement of costs presented net, and we applied the revenue
                                         recognition criteria in SAB104 (Topic 605) since we have not yet adopted ASC 606.</P>


</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>39.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    revise your disclosure to address how you account for research revenue when there is a possibility of contingent payments
    related to unsuccessful research and development activities, as referred to on page F-46. Provide us additional analysis to
    support your accounting for research revenue and identify the accounting literature you are relying upon.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Annual Financial Statements of
    Qualigen included in the Amended Registration Statement have been revised to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>New
Accounting Pronouncments, page F-45</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>40.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
    disclose that ASC 606 is effective for you for annual reporting periods beginning after December 15, 2019, including interim
    periods therein. Please clarify how you made this determination and how you considered the guidance in ASC 606-10-65-1(b).</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">The
                                         Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that
                                         the Annual Financial Statements of Qualigen included in the Amended Registration Statement
                                         have been revised to clarify the effective date of ASC 606 for the Company. ASC 606 is
                                         effective for the Company for annual reporting periods beginning after December 15, 2018,
                                         and interim periods in fiscal years beginning after December 15, 2019. Since Qualigen&rsquo;s
                                         fiscal year ends on March 31, and the combined company will have emerging growth status after
                                         the proposed merger, the combined company will adopt ASC 606 as of March 31, 2020.</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>5.
Equipment held for Lease, net, page F-47</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>41.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    provide us your analysis of the lease classification criteria under ASC 840-10-25-1, 840-10-25-42 and 25-43 for the leases
    in your multiple element arrangements.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">The Company acknowledges the Staff&rsquo;s comment and
                                                                              respectfully advises the Staff that under Qualigen&rsquo;s multiple element arrangements, per ASC 840-10-25, Qualigen
                                                                              classifies its leases as operating leases. The arrangements do not meet any of the criteria for classification as a
                                                                              sales-type or direct financing lease. The leases do not involve a third-party creditor for financing, therefore they are not
                                                                              leveraged leases. Therefore, Qualigen recognizes lease income over the term of the lease.</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>12.
License Agreements, page F-51</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>42.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
    your various agreements where you might be required to make future sponsored research payments, milestone payments, funding
    payments, and royalty payments, please separately disclose possible future payments or range of payments, as well as royalty
    percentages. In addition, describe the milestones related to the milestone payments.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Annual Financial Statements of
    Qualigen included in the Amended Registration Statement have been revised to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>43.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    disclose details of the contingent payments related to the partnership with Sekisui, as referred to on page F-46.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Annual Financial Statements of
    Qualigen included in the Amended Registration Statement have been revised to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Interim
Financial Statements of Qualigen, Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Balance
Sheets, page F-62</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>44.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rather
    than presenting the balance sheet for the end of prior period dated December 31, 2018, please revise to present the balance
    sheet as of March 31, 2019, representing the end of the most recent annual period. Refer to Rule 8-03 of Regulation S-X.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Annual Financial Statements of
    Qualigen included in the Amended Registration Statement have been revised to address this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>12.
License Agreements, page F-78</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>45.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
    disclose here and on page 193 that as of December 31, 2019 you have a payment obligation due to Sekisui related to your agreement.
    Please explain to us in further detail the reason for this payment obligation. In addition, you refer to $7.2 million in future
    financing. Clarify your disclosure to more clearly identify the party that is providing the funds and the party that is receiving
    the funds, and the amount that has been provided to date.</B></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the Annual Financial Statements of
    Qualigen included in the Amended Registration Statement have been revised to provide the information requested by this comment.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">Securities and Exchange Commission</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">March
                                         13, 2020</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Consent
of Independent Registered Public Accounting Firm, page II-7</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U></U></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46.
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Please
    have your auditor correct the report date contained in the accountants&rsquo; consent. </B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company acknowledges the Staff&rsquo;s comment and respectfully advises the Staff that the report date in the accountants&rsquo;
    consent has been corrected in the Amended Registration Statement.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
it would expedite the review of the information provided herein, please do not hesitate to call the undersigned at (212) 549-0216.
</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Wendy Grasso</I></FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    </TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy
    Grasso</FONT></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc:
Andrew J. Ritter, CEO of Ritter Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  B +0# 2(  A$! Q$!_\0
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MY.>U;=S%)-"4BN'@<])$"DC_ +Z!%>5^+;:6+XAZ1$][-*[>3B5@NY,R'I@
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(H!1110(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L!%$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BN*\9>-
MKCPIXCT*W-K'+IEV)6OI=I+P(NP!QSC:"^6X/%8%Q\2=3&H16S7FB:=;R:O=
MV)O;R)FC2.) R$_O4&23C.0.1Q0M1M6/5**X>7QG-ILFF376IZ3J6F7<%TS7
MUA$4C\R)=X /FN,;0^>3R.U4_#GCO6=6_L:RO+2T@U6XO98KZ%$?$4*1>8&7
M+9!(>(9/')XII7$W8]$HKD/$WBZY\*ZJ/MMLDNG74!6Q:)3YC78Z0MSCYQC:
M<#H<TEIK/B/4=0.CQ-IEMJ%E:PS:A,]O)+%YDF2(XU$BD8"\L6/;CGA+7^OZ
M_IKN#T.PHKS2^^(UU]LT6V6\T?1UN7NX;R?45,D<4L#!<*?,C&"<XR>XJ.Y^
M*$^D1Z7<ZN+--/FNKJ&6\CC<+<1Q)N22$%C@.> "6SV/>@=G>QZ?16)X6U'4
M=8T6/4]02UB6[_?6T,!+&.$C*AVR0S8Y.  ,XYQFLM?B-HC?$%_!_F@7:QY$
MI<;3+_SR_P!['/Z4VFGR]2;Z7Z'7T5@^(-;N=*U3P_:P)$R:C?&VF+@DJOEN
MV5P1@Y4=<TS5]9OO^$@M= TDVT=[-;O=27%S$TB11JP7[BLI8DGCYAC!/M2&
M=#17FWB#XBZKH=JL::?!=7]KJJ65[%$K'S(C$9=\0SD,5[$M@@CGK3;OXAZE
M<ZK=6NCMIS6YO;"WM;F2%Y 4N$+%F =<XP,8(II7V_K;_,'IN>ET5Q%WXTO=
M#?4M/U..VNM3MA;FW:W1H8Y_/<QH"I9RF&'/)XY'I4VH>(M8\/.;;57T^YFN
M+.XGM9;>%XE$D2;C&RL[$C'.X$=#P*3=E?\ K^M!I7=OZZ?YG8T5Y,/BY>+X
M;TK47T^W%X5N#J-HVY2ICMVF78<G:' 4@D-P>^*[#QQX[TOP)IUO=:@&D:XF
M6-(HS\Q&1N;Z*.??@4VK;DIWV.IHK+O=7C'ABYUC3Y(IXUM'N8'ZH^%+#IVK
MBH/BE;3Q>%C%?:3/-?QM)J<,$H=[<+ 9#A0Q*_,,?-FE_7Y_Y,>ZO_73_,])
MHKBHO%.L0:/I_B._2Q72;YX1]E2-UFMTE8*C-(6*N<LN0%7J>3CGG9/BKJ,6
MG>)1+9VL5_IUVR66]&\NX@$PB8XW9+*3S@CJO%/E=[=?^&_S_JP=+_UU_P C
MU>BN)G\67DZ7]];ZCHFF:=8W;6>[5-P^T2J!D;]ZB,9R!\KGC..U7O&'BB;P
M_P""6UZT-G(P,!W,QDA*NZJ2"",C#$@_2EY_UJ!U%%<%!\0GO-)U;Q%:1VTV
MAVS?9K-03YUU/N"Y)SA$+, !@D]>.E:-SKNL:'=VMOK#Z?/]N27[.]M"\7ER
MHA<(P9VW@A6^8%>G3FAZ*[_K2_Y M?Z^1UE%>6Z'\4KS5=*\/23VEO;WUW?+
M;W\)1L+&T32+)&-V<, ,9SW':MJS\7WES;:9JTVI^'[&RU)@UM8WKF*>2,MC
M(E+X+8(.T1]2!N[TW%IV%?0[BBLOQ%K]CX8T&ZU?4) EO;INQGESV4>Y/%0>
M$O%%CXP\.6VL6!PDHQ)$6!:)QU0^X_E@TAFW17*V&LZWKSW-YI/]G)86]W):
MB&Z23S)_+;:S>8IQ'R&P-C9P.1GC#U+XF1Z9%XPBN;S2(+_29"NGVTTNUY_W
M2L,J7!;YB1\N*/Z_+_,=M;?U_6AZ-17G]OX^OG>[@>VMFN#>6=G9@!E4M-"L
MC%SD\#+'C'0#WKIDO=2TC3K^[U^?3Y+>UB,PN+5'AR "6#1LS8Q@8.\Y]!0]
M+MB6MK&U17GNE?$&_P#^$7OKK6M/ABUFVGAB%I$65#Y^WR22<D#Y\,?56K4'
MB:72;R^AUC6M NFM+9[F6WM"8KF$* V#$7<L,?Q?+VXYX&K;_P!=06NW]=#K
MJ*XY/$6LV5GI>JZJM@-/U&:&+R(8W66U\WA,N6(DY*@X5,9[XK3\8>*['P9X
M<N-8OLNL?RQPJ<-*YZ*/3Z]J&K;@M=C>HK(TO7;?Q#X9CUC1I4E6> O#N&0'
MQ]U@".0>",UQEE\2KRZU+PVAM;9;.[MD;4Y"K!K>:0.$5>< ;HV'.3R*=M;/
M^M_\OR[ATN>E45Y_=>-=:/@;3=2L+6SFUK59F%E;NCB-HP6?)&[/^K7.<]2/
MI4?B/XEQZ;IWAZ\MYK>SL]8B:07]W;2310L%!",J,I!))&<\8/!I6_R_K^M]
M /1**X:3QZECKF@V^J7VBVUAJ&GRW,ET+G]T9%*A1'(Q4%2&/49K)L?B5J5\
M!)%'I\D++J;QR1JQ#+;D>60=V""#SZ]L4/2_S_#_ (8%J>GT5YIHGQ,N]4@\
M,B:UM[>ZO)Y(=2A*MF+;"959/FX##:1G/!K3L_%]Y<VVF:M-J?A^QLM28-;6
M-ZYBGDC+8R)2^"V"#M$?4@;N]-Q:=A7TN=Q17&-JGB=/'0T1M0T?[*;0WI?^
MSI=X02!=F?/QG!^]C_@-0KXNU9O#C^+0EC_8:Y<6IC?SS"'VF3S-VW.!NV;/
M;=26O]>=OS'_ %^OY'<T5YA>?$^\L[_Q;9O:VZMIL3R:9,RMLN"D2NR/\W+#
M<#QC(SZ5Z-IUP]WIEI<R!0\T*2,%Z D G%.VEQ7UM_7]:EFBO/8_&&O1Z3JO
MB"X;3'TS3M0FMI+5+:193$DFPN)/,(+8YQLYQCBNEU[7)K";2["Q6(WNJ3&*
M!YE)CC"H79V ()P!]T$9)ZCK2_K\+_D-Z.W]:&[15'3!JJQ2)JS64DBMB.6T
M5D$BXZE&)VG.1C<WKGM67XU\8Z?X(\/R:K?_ +P[@D,"MAI6/8?AR30] 6IT
M5%4--UBTUC1(=6T^59K:>+S8V'TZ'W!X(]JX#PS\1+_56T%I=3T&^FU*3RY]
M.L8REQ:#:QWL3,W V@$%5Z_@7;6P=.8].HKSOPQXVO-=O6CN/$?AJUF6^FMQ
MIGD'[2Z(Y48)N.I SG9^%7X/%^H2?"R\\4-#;?;88+B18PK>63&S 9&[./E&
M>:72_P#6H=;':T5YIK_Q"UK3(-6:SL;2YEM'T]88BK9D,_WA][KV'IWS4TGQ
M.!O;A[6"*>R.GVL]LIRLAGFE,6QSR  < \9&#UIV8KH]%HKG-,U>['B!])O]
M9T"ZN!&7:VM"8;B(\$ QEW+#!SN^7MQSQ7\;?$#2/ T=BVHDO)=S+&L:'YE3
M/S2'V'ZTNWF,ZNBL;7]9.G^#]0UO3VAG,-D]S S?,CX4LIX(R#QT-8VE>)-6
MAUJRL=9FT^>*]TU[\2VMN\'V<+MR'#2/D'?P>.G2CO\ UW?Z,.E_ZZ?YH[*B
MO.--^(6IW7ASQ%>W-I:PW=G9MJ.GQA6VRVK*QB9^>3E3G!'4=*CL?'VIS6\4
MT5_HFL"33Y;J;^SHF7["ZQ[U67]Z^03\N/E/!_ >F_\ 6_\ D_GH.U]/ZZ?Y
MH]+HKR_4OB=<V5SHMK/-IFF27^FQ7JSW\,I@GD;K$'5OW0']YMV,CCU](>\B
MM]/-Y<R11Q)%YLCJVY% &20>X]Z;5KWZ?H2G>UNI8HKE?!'C[2?'=I=S:<6C
MDMIFC>%S\VW/RO\ 1A^1R*N:?K=S=^,M:T>1(A;V,%O)&R@[R9-^<G./X1C
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M)EG"&=G1F(R6&\9"XV@=?>IOI?\ K:X[:V_K>WYG>45A^'M=.H>"M/U[43#
M9K)+F<H"$3*Y.,DG'XFJ/@CQ]I/CNTNYM.+1R6TS1O"Y^;;GY7^C#\CD53BT
MW'L2G=7.JHKC+WQW:Z5XRU31]4OM,L;:WL8KBV>YF$3R2,7R,LP!'RC@#/-4
MO#?C'6O%EII\%C_9UK>MIZ7MY-+ \L:;V951$#J>=I.2W'H<\):[?UO_ )#>
MF_\ 6W^9Z!17#P>-[RXUW1--^SVR/<7UW97P^9MCPIN!0Y'!X/(/!Q6?K?Q'
MN]&LM4N)XK>*&VUK^SOM7V=Y4MXO+5O,D16!8Y., KU'XGG_ %T_S0?U^?\
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M!R:;37]>=OS8;_UZ_HCLO#7A\^&[:ZLH;OS;!KAI;2 QX-LK<F,'/*@Y(X&
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M"&,D%V9/,.Z1AQNR /3UFU'X9VLO&F:G=V:OI\VGRK<S378:)U 7;YDGR;2
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M\UT\S_6")]X"@\GYE;!/'I5FR\&K97NM3I?%EU*RAM ABYB$<;)NSGYLYSC
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MC+7/6/B[7;71-+T[4=3NC+?ZO%-8W7G-OEA^T[)86;.3MXX_NM[417-9=_\
M-?\  8/2_E_DW_FCT>V^'EM9^!=6\-V]TD)U,R/++%!MCC9\#Y(]WRJ !A=W
MXUK:AX>EFO;+4M.O([74[2!K=998/-C>-MI*L@92>5!&&&#ZUO447?\ 7I;\
M@_K]3D?^$'#S65U-J'F7L>IC4KJ4PX$[B,QA%7=\B@$ <MT[DYIWA'P-;>$-
M5UNZL[IGMM2E22.W*8^SA0?E!R<C+'' P.*ZRBB_]?=_D@>N_P#7]7"BBBD
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
